Notable Labs, Ltd.

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Notable Labs, Ltd. trades as NTBL on NASDAQ. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $310,000 of revenue and -$11.26M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Notable Labs, Ltd. can be compared against peers such as Aravive, Inc., Athenex, Inc., Biophytis S.A., Eiger BioPharmaceuticals, Inc., Fresh2 Group Limited, Midatech Pharma plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.39M, beta of -2.36, and return on equity of -74.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

NTBL currently shows total debt of $2.05M and beta of -2.36. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SEC STAFF ACTION (2025-08-18 00:00:00), 25-NSE (2025-03-05 00:00:00), 8-K (2024-10-16 00:00:00), 8-K (2024-10-15 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.notablelabs.com

For Israeli stocks, verify official filings and local reports before publishing the thesis.